Show simple item record

dc.contributor.authorNeuzil, Jirien_US
dc.contributor.authorDyason, Jeffreyen_US
dc.contributor.authorLambrechts, Ruthen_US
dc.contributor.authorDong, Lan-fengen_US
dc.contributor.authorProchazka, Lubomiren_US
dc.contributor.authorWang, Xiufangen_US
dc.contributor.authorScheffler, Immoen_US
dc.contributor.authorRalph, Stephenen_US
dc.contributor.editorP.L. Pedersenen_US
dc.date.accessioned2017-04-24T09:20:15Z
dc.date.available2017-04-24T09:20:15Z
dc.date.issued2007en_US
dc.date.modified2010-08-30T07:04:13Z
dc.identifier.issn0145479Xen_US
dc.identifier.doi10.1007/s10863-006-9060-zen_AU
dc.identifier.urihttp://hdl.handle.net/10072/18479
dc.description.abstractRecently mitochondria in cancer cells have emerged as the Achilles heel for tumour destruction. Anti-cancer agents specifically targeting cancer cell mitochondria are referred to as 'mitocans'. These compounds act by destabilising these organelles, unleashing their apoptogenic potential, resulting in the efficient death of malignant cells and suppression of tumour growth. Importantly, at least some mitocans are selective for cancer cells, and these are represented by the group of redox-silent vitamin E analogues, epitomised by a-tocopheryl succinate (a-TOS). This compound has proven itself in pre-clinical models to be an efficient anti-cancer agent, targeting complex II of the respiratory chain to displace ubiquinone binding. We propose that disrupting the electron flow of mitochondrial complex II results in generation of superoxide, triggering mitochondrial destabilisation and initiation of apoptotic pathways. Moreover, a-TOS is selective for cancer cells with their reduced anti-oxidant defenses and lower esterase activity than the normal (non-malignant) counterparts. In this mini-review we discuss the emerging significance of mitocans, as exemplified by a-TOS.en_US
dc.description.peerreviewedYesen_US
dc.description.publicationstatusYesen_AU
dc.languageEnglishen_US
dc.language.isoen_AU
dc.publisherSpringeren_US
dc.publisher.placeNew York, USAen_US
dc.relation.ispartofstudentpublicationNen_AU
dc.relation.ispartofpagefrom65en_US
dc.relation.ispartofpageto72en_US
dc.relation.ispartofissue1en_US
dc.relation.ispartofjournalJournal of Bioenergetics and Biomembranesen_US
dc.relation.ispartofvolume39en_US
dc.rights.retentionYen_AU
dc.subject.fieldofresearchcode270106en_US
dc.titleMitocans as anti-cancer agents targeting mitochondria: lessons from studies with vitamin E analogues, inhibitors of complex IIen_US
dc.typeJournal articleen_US
dc.type.descriptionC1 - Peer Reviewed (HERDC)en_US
dc.type.codeC - Journal Articlesen_US
gro.date.issued2007
gro.hasfulltextNo Full Text


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record